Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.57 |
| ▸ | CTSL | P07711 | 6/20 | 0.54 |
| ▸ | CTSS | P25774 | 5/20 | 0.54 |
| ▸ | CTSB | P07858 | 5/20 | 0.54 |
| ▸ | CASP1 | P29466 | 3/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL44988 | 0.99 | CTSK (0.56) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL6675104 | 0.95 | CTSK (0.54) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL27919626 | 0.92 | CTSK (0.57) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL2912589 | 0.89 | CASP1 (0.60) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL7583002 | 0.89 | CASP1 (0.60) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL2912586 | 0.89 | CASP1 (0.60) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL20827013 | 0.88 | CASP1 (0.55) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL7975561 | 0.87 | CASP1 (0.55) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL3012469 | 0.87 | CASP1 (0.56) | CTSKCTSLCTSSCTSBCASP1 | |
| SCHEMBL3012475 | 0.87 | CASP1 (0.56) | CTSKCTSLCTSSCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| WO-2021073643-A1 | DRUG FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | 正大天晴药业集团股份有限公司 | 2021-04-22 | — | — | WO | disclosed |
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3456711-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | CTSK 76/4885CTSL 36/4885CTSS 72/4885 |
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CASP1, CASP14, CASP2 | CTSK 135/4885CTSL 73/4885CTSS 174/4885 |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CASP1, CASP14, CASP2 | CTSK 135/4885CTSL 73/4885CTSS 174/4885 |
| US-20190135733-A1 | CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF | CASP1, CASP14, CASP2 | CTSK 76/4885CTSL 36/4885CTSS 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.